Table 2.
Clinical trials of OVs in combination with immunotherapy
| Combination strategy | OV type | OV mutant | Combination agent | Targeted cancer | Trial phase | Trial status | Trial No. |
|---|---|---|---|---|---|---|---|
| Immunotherapy | HSV-1 | T-Vec |
Pembrolizumab (anti-PD1) |
Melanoma | II, III |
Active (not recruiting) |
|
| Pembrolizumab | Head and neck cancer | I |
Active (not recruiting) |
NCT02626000 | |||
|
Ipilimumab (anti-CTLA4) |
Sarcoma | II | Recruiting | NCT03069378 | |||
| Ipilimumab | Melanoma | I/II | Active (not recruiting) | NCT01740297 | |||
|
Ipilimumab + Nivolumab (anti-PD1) |
Breast cancer | I | Recruiting | NCT04185311 | |||
|
Atezolizumab (anti-PD-L1) |
Breast cancer, colorectal cancer | I | Recruiting | NCT03256344, NCT03802604 | |||
| HF10 | Ipilimumab | Melanoma | II | Completed | NCT02272855 | ||
| Nivolumab | Melanoma | II | Active (not recruiting) | NCT03259425 | |||
| Adenovirus | LOAd703 | Atezolizumab | Melanoma | I/II | Recruiting | NCT04123470 | |
| VCN-01 |
Durvalumab (anti-PD-L1) |
Head and neck cancer | I | Recruiting | NCT03799744 | ||
| Telomelysin | Pembrolizumab | Advanced solid tumors | I | Recruiting | NCT03172819 | ||
| ONCOS-102 | Durvalumab | Peritoneal malignancies | I/II | Recruiting | NCT02963831 | ||
| Reovirus | Reolysin® | Pembrolizumab | Pancreatic cancer | II | Active (not recruiting) | NCT03723915 | |
| Nivolumab | Multiple myeloma | I | Recruiting | NCT03605719 | |||
|
Vaccinia virus Vaccinia virus |
Pexa-Vec Pexa-Vec |
Ipilimumab | Advanced solid tumors | I | Recruiting | NCT02977156 | |
| Immunotherapy |
Durvalumab + Tremelimumab (anti-PD-L1) |
Colorectal cancer | I/II | Recruiting | NCT03206073 | ||
| Nivolumab | Hepatocellular carcinoma | I/II | Active (not recruiting) | NCT03071094 | |||
| Coxsackie virus | CAVATAK | Pembrolizumab | Melanoma | I | Completed | NCT02565992 | |
| Pembrolizumab | Non-small cell lung carcinoma, bladder cancer | I | Completed | NCT02043665 | |||
| Ipilimumab | Melanoma | I | Completed | ||||
| Pembrolizumab | Non-small cell lung carcinoma | I | Active (not recruiting) | NCT02824965 | |||
| Multi-therapy | Adenovirus | LOAd703 |
Atezolizumab + Gemcitabine + Nab-paclitaxel |
Pancreatic cancer | I/II | Recruiting | NCT02705196 |
| ONCOS-102 | Pembrolizumab + Cyclophosphamide | Melanoma | I | Active (not recruiting) | NCT03003676 | ||
| Reovirus | Reolysin® | Pembrolizumab + Gemcitabine + FOLFIRI | Pancreatic cancer | I | Completed | NCT02620423 |